Dalia Bejjani, MD

Clinical Assistant Professor

Internal Medicine

Emaildelbejjani@ascension.org

If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Bio

Dr. Bejjani is board certified in Infectious Diseases and Internal Medicine. She maintains membership in the Infectious Diseases Society of America and has held academic appointments since 2007. Dr. Bejjani has numerous publications and national/international abstracts and presentations. She currently practices at the Seton Trinity Facility.

Fingerprint Dive into the research topics where Dalia Bejjani is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

rosiglitazone Medicine & Life Sciences

HIV Medicine & Life Sciences

Carotid Intima-Media Thickness Medicine & Life Sciences

Placebos Medicine & Life Sciences

Reverse Transcriptase Inhibitors Medicine & Life Sciences

Peroxidase Medicine & Life Sciences

Thymidine Medicine & Life Sciences

Peroxisome Proliferator-Activated Receptors Medicine & Life Sciences

Research Output 2007 2013

8 Article

13 Citations (Scopus)

A case of endocarditis caused by lactococcus garvieae and suggested methods for identification

Navas, M. E., Hall, G. & El Bejjani, D., Jun 1 2013, In : Journal of Clinical Microbiology. 51, 6, p. 1990-1992 3 p.

Research output: Contribution to journal › Article

Lactococcus

Endocarditis

Fishes

Gram-Positive Cocci

Heart Valves

4 Citations (Scopus)

Changes in inflammation, oxidative stress, mitochondrial DNA content after rosiglitazone in HIV lipoatrophy

Tungsiripat, M., El-Bejjani, D., Rizk, N., Hu, B., Ross, A. C., Walker, U. A., Lebrecht, D., Milne, G., Storer, N. & McComsey, G. A., Oct 1 2012, In : Journal of AIDS and Clinical Research. 3, 8

Research output: Contribution to journal › Article

rosiglitazone

Peroxisome Proliferator-Activated Receptors

Mitochondrial DNA

Oxidative Stress

Tumor Necrosis Factor Receptors

9 Citations (Scopus)

Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo

Tungsiripat, M., Bejjani, D., Rizk, N., Dogra, V., O'Riordan, M. A., Ross, A. C., Hileman, C., Storer, N., Harrill, D. & McComsey, G. A., Mar 1 2011, In : AIDS Research and Human Retroviruses. 27, 3, p. 295-302 8 p.

Research output: Contribution to journal › Article

rosiglitazone

Carotid Intima-Media Thickness

Placebos

HIV

Vascular Cell Adhesion Molecule-1

27 Citations (Scopus)

Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens

Tungsiripat, M., Bejjani, D. E., Rizk, N., O'Riordan, M. A., Ross, A. C., Hileman, C., Storer, N., Harrill, D. & McComsey, G. A., Jun 1 2010, In : AIDS. 24, 9, p. 1291-1298 8 p.

Research output: Contribution to journal › Article

rosiglitazone

Reverse Transcriptase Inhibitors

Thymidine

Placebos

Peroxisome Proliferator-Activated Receptors

171 Citations (Scopus)

Relationship between Inflammatory Markers, Endothelial Activation Markers, and Carotid Intima-Media Thickness in HIV-infected Patients Receiving Antiretroviral Therapy

Ross, A. C., Rizk, N., O'Riordan, M. A., Dogra, V., El-Bejjani, D., Storer, N., Harrill, D., Tungsiripat, M., Adell, J. & McComsey, G. A., Oct 1 2009, In : Clinical Infectious Diseases. 49, 7, p. 1119-1127 9 p.

Research output: Contribution to journal › Article

Carotid Intima-Media Thickness

HIV

Internal Carotid Artery

Vascular Cell Adhesion Molecule-1

Therapeutics